See All Slides - tctmd.com

Slides

Presentation The Structural Heart Disease Summit 2018

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

Presenter: Howard C. Herrmann, Allan Schwartz, Eberhard Grube

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

LAA Closure Plus: TAVR, MitraClip, PFO Closure, and More

Presenter: Ramon Quesada

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Post LAA Closure Anticoagulation/Antiplatelet Regimens: Data and Practice

Presenter: Josep Rodés-Cabau

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of LAA Closure Devices: Similarities and Meaningful Differences

Presenter: Reda Ibrahim

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Submassive PE, Paradoxical Embolism, Residual DVT, and Large PFO: Thrombolysis, Filter, or Both?

Presenter: Horst Sievert, Robert J. Sommer, Varda Singhal, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A)

Presenter: Francesco Maisano

June 22, 2018

Program Update: The LOTUS TAVR System: Design Characteristics, Clinical Data, and Future Vision

Presentation The Structural Heart Disease Summit 2018

Program Update: The LOTUS Edge TAVR System: Design Characteristics, Clinical Data, and Future Vision

Presenter: Axel Linke, Vinod H. Thourani, Ted Feldman

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Presenter: Howard C. Herrmann, Allan Schwartz, Jonathan Afilalo

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Use of Appendage Lobe to Deploy Watchman Device in a Very Shallow Left Atrial Appendage: Access Is Success

Presenter: Horst Sievert, Robert J. Sommer, Sandeep Sehgal, MD

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

Presenter: Howard C. Herrmann, Allan Schwartz, Suzanne V. Arnold

June 22, 2018

Advertisement

Slides

TAVR to Treat Pure Aortic Regurgitation: Published and Personal Experiences (With Case Examples)

LAA Closure Plus: TAVR, MitraClip, PFO Closure, and More

Post LAA Closure Anticoagulation/Antiplatelet Regimens: Data and Practice

The Spectrum of LAA Closure Devices: Similarities and Meaningful Differences

Submassive PE, Paradoxical Embolism, Residual DVT, and Large PFO: Thrombolysis, Filter, or Both?

Early Commercial Experience Using the PORTICO Transcatheter Aortic Valve: 30-Day Outcomes in 973 Patients Enrolled in the Portico I Study (Cohort A)

Program Update: The LOTUS Edge TAVR System: Design Characteristics, Clinical Data, and Future Vision

Frailty Assessment of TAVR and SAVR Patients: The Essential Frailty Toolset

Use of Appendage Lobe to Deploy Watchman Device in a Very Shallow Left Atrial Appendage: Access Is Success

Who Shouldnt Undergo TAVR? Can We Identify the Futile Non-responders?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content